Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SABBOBCATon Jan 13, 2021 12:42pm
186 Views
Post# 32285547

RE:The dreadful deal

RE:The dreadful dealSPCEO I hope that Dubuc will give you the time of day once he is able to more freely chat next week. We all are frustrated by the deal and lack of engagement from management. I would hope they try to med the relationship and provide some insight. I would love to hear your summary of that conversation when it happens. I think it will be very telling for us to see if there is an issue with management. As you know was frustrated was frustrated by Luc's style, but very much respected his vision and foresight with the cancer program. Paul seems to be a good fit, but it is still early in the game and in the middle of a pandemic. Dubuc on the other hand has always frustrated me. The responses I get to questions are dismissive and the shareholder engagement is weak. This deal made me lose all respect for him as a CFO. He has work to do to earn that back and I would hope the board looks at the reaction to this deal and realizes what a colossal misstep it looks like. Now we could be wrong and there may be something else going on, but if not, I would be extremely frustrated if top comp and bonuses are dolled out in the coming months. If love to get you thoughts on the matter.
<< Previous
Bullboard Posts
Next >>